Home
About
Overview
Sharing Data
ORCID
Help
History (16)
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
Perioperative visual loss: what do we know, what can we do?
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
See All 16 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167.
View in:
PubMed
subject areas
Aged
Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung
Female
Humans
Lung Neoplasms
Male
Programmed Cell Death 1 Receptor
Retrospective Studies
authors with profiles
Marina Chiara Garassino